Boston — Syntis Bio, Inc. has appointed Matthew Dallas as chief financial officer as the clinical-stage biopharmaceutical company advances its oral therapeutics pipeline.
Dallas brings more than 25 years of financial and management experience in the life sciences industry. Syntis Bio is developing oral therapies that leverage the small intestine, including SYNT-101, its lead investigational program for obesity.
“With Matt’s appointment, we continue to assemble a leadership team with the expertise and experience needed to scale Syntis Bio’s financial and business infrastructure as we rapidly advance multiple pipeline programs, including SYNT-101, the Company’s lead investigational program for the treatment of obesity,” said Rahul Dhanda, Chief Executive Officer of Syntis Bio. “Matt has navigated the full arc of building a biopharmaceutical company – from public and private financing strategies to scaling operations to forging partnerships. He will be a tremendous asset as we build our financial foundation and look towards our next phase of growth and long-term success.”
Dallas most recently served as chief financial officer of Pulmocide, where he oversaw the company’s capital strategy, finance and investor relations functions.
Before Pulmocide, Dallas was chief financial officer of Zealand Pharma, a Danish biotechnology company that develops peptide-based medicines, with a focus on metabolic diseases such as diabetes and obesity.
He previously held CFO roles at AVEO Oncology and CoLucid Pharmaceuticals. At CoLucid, Dallas helped lead the company’s initial public offering and later acquisition by Eli Lilly and Company.
“I’m excited to join Syntis and for the opportunity to be part of a company developing the next generation of solutions for metabolic health,” said Matthew Dallas, Chief Financial Officer of Syntis Bio. “I look forward to working closely with Rahul and the leadership team to scale our business and support it through financial strategies that translate into significant value creation while delivering new therapies to patients who need them.”
Dallas holds a bachelor’s degree in finance from the University of Tennessee, Knoxville, and serves on the university’s Finance Department Advisory Council.
